trial

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCTId NCT02566057
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 36 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2017-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2014-07-10
Primary completion
2017-12-31
Eligibility
ALL · 15 Years · 64 Years

Interventions & indications

Drugs
PGx testing guided treatment (PGT)

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
Genomind, LLCCollaborator

Investigators

1
Jianping Zhang, MD, PhDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
36
Phase
NA
Primary Completion Date
2017-12-31
Status
COMPLETED
relationships
The graph out of here
drug
PGx testing guided treatment (PGT)
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
Genomind, LLC
company
indication
Bipolar Disorder
indication
Schizophreniform Disorder
indication
Psychotic Disorders
indication
investigator
Jianping Zhang, MD, PhD
person